NCCN临床实践指南_前列腺癌早期检测(2019.V2)英文版
62页1、Version 2 2019 05 31 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Prostate Cancer Early Detection Version 2 2019 May 31 2019 Continue NCCN org NCCN Guidelines Version 2 2019 Prostate Cancer Early Detection Version 2 2019 05 31 19 2019 National Comprehensive Cancer Network NCCN All rights rese
2、rved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion Peter R Carroll MD MPH Chair UCSF Helen Diller Family Comprehensive Cancer Center J Kellogg Parsons MD MHS Vice Chair UC San Diego Moores Cancer Center Gerald Andriole MD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine Robert R Bahnson MD The Ohio State University Comprehensive C
3、ancer Center James Cancer Hospital and Solove Research Institute Sigrid Carlsson MD Memorial Sloan Ketering Cancer Center Erik P Castle MD Mayo Clinic Cancer Center William J Catalona MD Robert H Lurie Comprehensive Cancer Center of Northwestern University Douglas M Dahl MD Massachusetts General Hospital Cancer Center John W Davis MD The University of Texas MD Anderson Cancer Center Jonathan I Epstein MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Ruth B Etzioni PhD 123 2312 2
4、319 Footnote c was modified If there is a known or suspected cancer susceptibility gene referral to a cancer genetics professional is recommended BRCA1 2 pathogenic mutation carriers have are associated with an increased risk of prostate cancer before age 65 years and prostate cancer in men with germline BRCA2 mutations occurs earlier and is more likely to be associated with prostate cancer mortality Information regarding germline mutations should be used as part of the discussion about prostate
5、 cancer screening Consequently it is reasonable for men with germline BRCA1 2 mutations to consider beginning shared decision making about PSA screening at age 40 and to consider screening at annual intervals rather than every other year Footnote e was modified Testing after 75 years of age should be done only in very healthy men with little or no comorbidity especially if they have never undergone PSA testing to detect the small number of aggressive cancers that pose a significant risk if left
《NCCN临床实践指南_前列腺癌早期检测(2019.V2)英文版》由会员沧海****3分享,可在线阅读,更多相关《NCCN临床实践指南_前列腺癌早期检测(2019.V2)英文版》请在金锄头文库上搜索。
洁厕灵企业技术标准范例
发电企业热工设备检修规程
发电企业热控日常点检标准
发电企业汽机(含燃机)技术监督细则
发电企业电气设备保护及安全自动装置投退和定值变更管理标准
继电保护定值变更通知单
继电保护及安全自动装置投退审批表
电气保护定值更改申请单
化工企业粉尘涉爆企业整体安全风险等级评估方法
化工企业安全检查管理规程
电气安全管理规程范例
农业企业绿色食品大棚生菜生产操作规程
农业企业绿色食品桃园管理规程
农业企业绿色食品早春蕹菜生产操作规程
农业企业绿色食品大棚蚕豆促早栽培生产技术操作规程
农业企业绿色食品荠菜种植规程
农业企业绿色食品青椒种植规程
农业企业绿色食品筒篙种植规程
农业企业绿色食品油麦菜种植规程
农业企业绿色食品木耳菜种植规程
2023-05-11 11页
2022-09-05 10页
2022-08-18 10页
2022-08-18 6页
2022-08-18 7页
2022-08-18 3页
2022-08-18 5页
2022-08-18 9页
2022-08-18 7页
2022-08-18 4页